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Ubiquitination and proteasomal degradation of
ATG12 regulates its proapoptotic activity
Martina Haller,1,2 Andreas K Hock,1 Evangelos Giampazolias,1,2 Andrew Oberst,3 Douglas R Green,4 Jayanta Debnath,5
Kevin M Ryan,1 Karen H Vousden,1 and Stephen W G Tait1,2,*
1Cancer Research UK Beatson Institute; Glasgow, UK; 2Institute of Cancer Sciences; University of Glasgow; Glasgow, UK; 3Department of Immunology; University of Washington;
Seattle, WA USA; 4Department of Immunology; St. Jude Children’s Research Hospital; Memphis, TN USA; 5Department of Pathology and Helen Diller Family Comprehensive Cancer
Center; University of California, San Francisco; San Francisco, CA USA
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Abbreviations: Act D, actinomycin D; ATG, autophagy-related; BCL2L1, BCL2-like 1; BH3, BCL2 homology domain 3; CHX,
cycloheximide; HBSS, Hank’s balanced salt solution; LC3/MAP1LC3, microtubule-associated protein 1 light chain 3; MEF, mouse
embryonic fibroblast; RNAi, RNA interference; UB, ubiquitin; UBL, ubiquitin-like protein.
During macroautophagy, conjugation of ATG12 to ATG5 is essential for LC3 lipidation and autophagosome
formation. Additionally, ATG12 has ATG5-independent functions in diverse processes including mitochondrial fusion
and mitochondrial-dependent apoptosis. In this study, we investigated the regulation of free ATG12. In stark contrast to
the stable ATG12–ATG5 conjugate, we ﬁnd that free ATG12 is highly unstable and rapidly degraded in a proteasome-
dependent manner. Surprisingly, ATG12, itself a ubiquitin-like protein, is directly ubiquitinated and this promotes its
proteasomal degradation. As a functional consequence of its turnover, accumulation of free ATG12 contributes to
proteasome inhibitor-mediated apoptosis, a ﬁnding that may be clinically important given the use of proteasome
inhibitors as anticancer agents. Collectively, our results reveal a novel interconnection between autophagy, proteasome
activity, and cell death mediated by the ubiquitin-like properties of ATG12.
Introduction
Macroautophagy (hereafter termed autophagy) and protea-
some-mediated degradation constitute the cell’s 2 major means
of protein turnover.1,2 Proteasomal degradation typically allows
the selective turnover of short-lived proteins whereas autophagy
is often considered a process that favors degradation of long-lived
proteins. Autophagy and proteasome-mediated degradation are
highly interconnected, such that perturbation of one pathway
can impact on the other.3-6 Importantly, deregulation of either
process likely underpins many diseases linked to defective protein
degradation such as Alzheimer’s disease.7,8
At a mechanistic level, autophagy and proteasome-mediated
degradation share several similarities. Ubiquitination is often
required to target proteins for proteasomal degradation; this pro-
cess requires step-wise transfer of ubiquitin onto the target pro-
tein by 3 classes of enzyme (E1, 2, 3).9 In an analogous fashion,
2 converging ubiquitin-like conjugation pathways are essential
for autophagy. In one pathway, the ubiquitin-like protein (UBL)
ATG12 is transferred from an E1-like enzyme, ATG7 via
ATG10 (E2-like) forming a covalent attachment with ATG5.10
Separately, the UBL MAP1LC3B/LC3B (Atg8 in yeast) is
transferred from ATG7 onto ATG3 (E2-like). Serving an E3-
like function, the ATG12–ATG5 conjugate (together with
ATG16L1) is required for LC3B conjugation to phosphatidyleth-
anolamine that drives autophagosomal membrane expansion.10
Besides its essential role in autophagy, the UBL ATG12 also
carries out various autophagy-independent roles. These include
induction of mitophagy, promotion of mitochondrial fusion and
activation of mitochondrial apoptosis.11-13 Importantly, ATG12
has been shown to mediate these functions independently of its
ability to conjugate to ATG5. ATG12 conjugation to ATG3 pro-
motes mitochondrial fusion and restricts mitochondrial mass
whereas free ATG12 directly promotes mitochondrial apoptosis in
a similar manner to proapoptotic BH3-only proteins.12,13 Given
these autophagy (and ATG5)-independent functions of ATG12,
in this study we investigated the regulation of free ATG12.
Results
Free ATG12 is rapidly degraded in a proteasome-dependent
manner
While investigating ATG12 regulated mitophagy we noted
that the free form of ATG12 was expressed at very low levels
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compared with the ATG12–ATG5 conjugate (Fig. 1A). We rea-
soned that this might either be due to efficient and complete con-
jugation of ATG12 to ATG5, instability of free ATG12 or a
combination thereof. To address this, the stability of free ATG12
was examined following treatment of cells with the protein-
translation inhibitor cycloheximide (CHX). Strikingly, endoge-
nous ATG12 was rapidly depleted to below detectable levels fol-
lowing 2-h CHX treatment (Fig. 1B). In a similar manner,
ectopically expressed free ATG12 was also rapidly turned over,
consistent with previous findings (Fig. 1C).14 Densitometric
Figure 1. Free ATG12 is rapidly degraded in a proteasome-dependent manner (A) Western blot detection of ATG12 in U2OS cells. (B) Endogenous ATG12
expression in U2OS cells following CHX treatment. (C) U2OS expressing empty vector or ATG12 were treated with CHX for various times and probed for
ATG12 expression. (D) U2OS cells were treated were treated for 8 h as indicated with MG132 and/or CHX and probed for ATG12 expression. (E) U2OS
were treated for 8 h with MG132 or lactacystin and examined for ATG12 expression. (F) U2OS expressing ATG12 were treated for 8 h with MG132 and/or
CHX as indicated and cell lysates were probed for ATG12 expression. ACT or TOMM20 were used as a loading control.
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analysis revealed a half-life of 30 min for
free ATG12 (Fig. S1). In contrast, levels
of ATG12–ATG5 conjugate were
unchanged following translational inhi-
bition over an 8-h time-period (Fig. 1B,
C, Fig. S1). Because the ubiquitin-pro-
teasome system is the major degradative
pathway for short-lived proteins, we
next investigated whether free ATG12
was degraded in a proteasome-depen-
dent manner. Treatment of cells with
the proteasome inhibitor MG132
increased endogenous free ATG12 pro-
tein levels and completely prevented
degradation of free ATG12 following
CHX treatment (Fig. 1D), demonstrat-
ing that free ATG12 is degraded in a
proteasome-dependent manner. Sup-
porting this, treatment of U2OS cells
with an alternative proteasome inhibi-
tor, lactacystin, also led to an accumula-
tion of endogenous free ATG12
(Fig. 1E). Consistent with ATG12
being degraded in a proteasome-depen-
dent manner, MG132 treatment also
increased levels of ectopically expressed
free ATG12 and prevented degradation
of free ATG12 following CHX treat-
ment (Fig. 1F). Taken together, these
data demonstrate that the free form of ATG12 is highly unstable
and degraded in a proteasome-dependentmanner.
Proteasomal degradation of free ATG12 is independent of
autophagy
Autophagy requires ATG12 conjugation via its C-terminal gly-
cine to ATG5 in a process that is catalyzed by ATG7 and ATG10.
We next determined whether autophagy contributed to the degra-
dation of free ATG12. Wild-type E1A and RAS-transformed
murine embryonic fibroblasts (MEFs) expressed readily detectable
ATG12–ATG5 conjugate but low amounts of free ATG12
(Fig. 2A). As expected, ATG12–ATG5 conjugate was completely
absent in Atg7-deficient MEFs, but, surprisingly, the level of free
ATG12 was similar to wild-type MEFs even though Atg7-deficient
MEFs expressed higher levels of Atg12 mRNA (Fig. 2A, Fig.
S2A). In both cases, MG132 treatment increased free ATG12 to
the same extent (Fig. 2A). Supporting this finding, proteasome
inhibitor also increased ATG12 expression in SV40 immortalized
MEFs deficient in Atg7 (Fig. S2B). These data demonstrate that
ATG12 can be targeted for proteasome-dependent degradation
independent of ATG7. To investigate whether other components
of the autophagy pathway influenced ATG12 stability, we per-
formed similar experiments in SV40 immortalized MEF deficient
in Atg3 or Atg5 (Fig. 2B, C). In both cases, MG132 treatment led
to an increase in free ATG12 levels. ATG12 was also stabilized to
a similar extent following proteasome-inhibitor treatment in cells
following ATG5 knockdown by RNA interference (RNAi)
(Fig. S2C). Finally, we analyzed the stability of ATG12 in which
its C-terminal glycine was mutated to alanine (G140A) and is
therefore unable to efficiently conjugate to ATG5.15 Similar to
ectopically expressed wild-type ATG12 (Fig. 1F), ATG12G140A
was highly unstable and degraded in a proteasome-dependent
manner (Fig. 2D). These results demonstrate that the rapid protea-
somal degradation of free ATG12 neither requires the ATG12–
ATG5 conjugation machinery nor autophagy.
Direct ubiquitination of free ATG12 regulates its
proteasomal degradation
The major means of targeting proteins for proteasomal degra-
dation is by poly-ubiquitination. Therefore, we addressed whether
ATG12 is directly ubiquitinated. Empty vector or ATG12 were
coexpressed with His-tagged ubiquitin (His-UB) in 293T cells
treated or not with MG132. Ubiquitinated proteins were isolated
by Dynabead affinity isolation and probed with anti-ATG12 anti-
body (Fig. 3A). Following ubiquitin affinity isolation, an ATG12
immunoreactive smear was detected, demonstrating that ATG12
is directly ubiquitinated. Furthermore, MG132 treatment
increased the amount of ubiquitinated ATG12 and, as expected,
led to a general increase in the level of protein ubiquitination
(Fig. 3A). We next assessed the contribution of ATG12 ubiquiti-
nation to its proteasome-mediated degradation. Ubiquitination
most often occurs on substrate lysine residues, therefore we
mutated all lysine residues in ATG12 to arginine (ATG12[K-]).
First, we examined whether ATG12[K-] remained functionally
Figure 2. Proteasomal degradation of free ATG12 protein occurs independent of autophagy (A) E1A
and Ras-transformed WT or Atg7 knockout MEF were treated for 8 h with MG132 and cell lysates were
probed for ATG12 expression. (B) Atg3 or (C) Atg5 knockout MEFs were treated with MG132 for 4 h
and 8 h and analyzed for ATG12 expression. (D) U2OS cells expressing ATG12G140A were treated for
8 h with MG132 and/or CHX as indicated and lysates were examined for ATG12 expression. In all
immunoblots, ACT was used as a loading control.
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Figure 3. Direct ubiquitination of free ATG12 regulates its proteasomal degradation (A) 293T cells expressing vector or ATG12 and His-ubiquitin were
treated with MG132 as indicated. Cell lysates were subject to His-tag afﬁnity isolation and immunoblotted for ATG12 and ubiquitin expression (B) Atg12
knockout MEFs, as well as MEFs stably expressing Atg12, were treated for 4 h with chloroquine, then examined for ATG12 and LC3B expression. (C) 293T
cells expressing ATG12 or ATG12[K-] together with His-ubiquitin, were treated as indicated, subject to His-tag afﬁnity isolation and probed for ATG12
and ubiquitin expression. (D) U2OS cells expressing ATG12 or ATG12[K-] and treated for 6 h with CHX and analyzed for ATG12 and TOMM20 expression,
densitometric analysis was performed using ImageJ software, normalizing to TOMM20 levels. (E) U2OS cells expressing ATG12[K-] were treated with
MG132 and/or CHX for 8 h as indicated and examined for ATG12 expression. ACT or TOMM20 were used as loading controls.
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active by stably expressing either WT ATG12 or ATG12[K-] in
Atg12 knockout MEF. Cells were treated with the lysomotropic
agent chloroquine to inhibit basal autophagy and assessed for
ATG12–ATG5 conjugation and LC3 lipidation (Fig. 3B).
Expression of ATG12[K-] restored ATG12–ATG5 conjugate for-
mation and LC3 lipidation to a similar extent as WT ATG12 in
Atg12-deficient MEFs, thereby demonstrating that lysineless
ATG12 retained functionality. Following this, we examined the
effect of removing lysines upon ATG12 ubiquitination. His-
tagged ubiquitin and WT or ATG12[K-] were coexpressed in cells
that were treated or not with MG132 and ubiquitinated proteins
were isolated by affinity isolation and probed for ATG12. Impor-
tantly, compared with WT ATG12, mutation of lysines in
ATG12 completely abolished its ubiquitination (Fig. 3C). This
argues that ATG12 is ubiquitinated solely on lysine residues and
not other possible acceptor residues such as its N terminus. We
aimed to define which ATG12 lysine(s) were subject to ubiquiti-
nation by extensive mutagenesis of single or closely grouped lysine
residues and assessing its effect upon ATG12 ubiquitination
(Fig. S3A). All ATG12 lysine-mutants displayed similar levels of
ubiquitination to WT ATG12, demonstrating that poly-ubiquti-
nation of ATG12 can occur on multiple lysine residues
(Fig. S3B). Using the ATG12[K-] mutant, we investigated the
role of ATG12 ubiquitination upon its stability. Cells expressing
either WT or ATG12[K-] were treated with CHX for 6 h and
examined for ATG12 protein level by western blot. Whereas 90%
of WT ATG12 was degraded with 6-h CHX treatment, 50% of
ATG12[K-] remained, supporting a role for ubiquitination in
proteasomal-degradation of ATG12 (Fig. 3D). Nevertheless, we
were intrigued that a significant pool of ATG12[K-] was still
degraded even though it was not ubiquitinated. As such, we inves-
tigated whether lysineless ATG12 was still subject to proteasome-
dependent degradation. Cells expressing ATG12[K-] were treated
with CHX in the presence or absence of MG132. Interestingly,
degradation of ATG12[K-] following CHX treatment could be
inhibited by proteasome inhibition (Fig. 3E). Together, these
data show that ATG12 is directly ubiquitinated and that ATG12
can be targeted for proteasomal degradation by ubiquitin-depen-
dent and -independent mechanisms.
Free ATG12 regulates proteasome inhibitor-mediated cell
death
ATG12 has previously been implicated in mitochondrial-
dependent apoptosis.13 This, coupled with our finding that free
ATG12 is turned over via the proteasome, led us to address
whether ATG12 contributes to proteasome inhibitor-mediated
toxicity. First, we examined whether proteasome inhibitor trig-
gered cell death via the mitochondrial apoptotic pathway. Cells
ectopically expressing antiapoptotic BCL2L1 were treated with
MG132 and analyzed for cell death by uptake of the cell imper-
meable dye SYTOX Green or by ANXA5-propidium iodide
staining and flow cytometry. BCL2L1 robustly protected against
MG132-mediated killing, confirming that MG132 predomi-
nantly engages the mitochondrial apoptotic pathway (Fig. 4A,
Fig. S4A). Next, we utilized RNAi to knock down ATG12 in
U2OS cells. Importantly, given the instability of free ATG12,
RNAi allowed us to selectively downregulate free ATG12 with
minimal effects upon levels of ATG12–ATG5 conjugate
(Fig. 4B). In accordance, no effect upon autophagy was observed
following ATG12 RNAi (Fig. S4B). We examined the effect of
depleting ATG12 upon proteasome inhibitor-mediated toxicity.
U2OS cells treated with control or ATG12 RNAi were incubated
with MG132 and monitored for cell death by uptake of the cell-
impermeable dye SYTOX Green or by ANXA5-propidium
iodide staining and flow cytometry. Consistently, RNAi knock-
down of ATG12 protected against proteasome inhibitor-medi-
ated toxicity (Fig. 4C, Fig. S4C). Two individual siRNA oligos
targeting ATG12 gave similar results (Fig. S4D, E). Extending
these findings, we examined whether depletion of ATG12 could
offer general protection against other prodeath stimuli including
starvation (HBSS) and actinomycin D (Act D) treatment. Similar
to proteasome inhibition, ectopic expression of antiapoptotic
BCL2L1 effectively blocked cell death induced by HBSS starva-
tion or Act D treatment demonstrating that these treatments kill
via mitochondrial-dependent apoptosis (Fig. S4F–H). Interest-
ingly, whereas ATG12 knockdown inhibited starvation induced
apoptosis, it had no effect upon Act D-mediated apoptosis
(Fig. 4D, E, Fig. S4I, J). Similar to ectopic BCL2L1 expression,
ATG12 knockdown promoted long-term clonogenic survival fol-
lowing starvation in-line with a proapoptotic function for
ATG12 residing upstream of the mitochondrial permeabilization
(Fig. 4F). The difference in requirement for ATG12 following
divergent prodeath stimuli prompted us to investigate levels of
free ATG12 following different treatments. Free ATG12
remained constant during starvation or, as before, increased fol-
lowing proteasome inhibitor treatment. In contrast, and in line
with its ability to inhibit transcription, free ATG12 levels were
rapidly depleted following Act D treatment (Fig. 4G).
Free ATG12 regulates proteasome inhibitor-mediated cell
death independently of autophagy
Ectopic expression of ATG12 has been shown to inhibit
autophagy.16,17 Therefore, we addressed whether the ability of
free ATG12 to promote cell death was modulated by autophagy.
For this purpose, we generated U2OS cells stably expressing a
dominant-negative ATG4B mutant (C74A).18 Verifying its
dominant negative effect, the accumulation of lipidated LC3B
following chloroquine treatment was prevented in ATG4BC74A
-expressing cells (Fig. 5A). We subjected ATG4BC74A or control
cells to HBSS starvation, MG132 or Act D treatment. Inhibition
of autophagy did not affect cell death induced by all 3 treatments
(Fig. S5). Finally, we knocked down ATG12 in autophagy-defi-
cient U2OS cells and subjected them to proteasome inhibitor or
HBSS starvation. Knockdown of ATG12 equally protected
autophagy- proficient and -deficient U2OS cells in response to
both stimuli (Fig. 5B, C), further arguing ATG12s proapoptotic
effects are independent of effects on autophagy.
Discussion
Here we investigated the regulation of ATG12 protein stabil-
ity; unlike the ATG12–ATG5 conjugate, we find that free
www.landesbioscience.com 2273Autophagy
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Figure 4. Free ATG12 promotes proteasome inhibitor-mediated cell death (A) U2OS cells stably expressing empty vector or BCL2L1 were treated with
MG132 and cell viability was determined by SYTOX Green staining using an Incucyte Imager; data represents the mean C/¡ standard error of the mean
(SEM) of 3 experiments at a representative time-point (24 h). (B) U2OS cells were assessed for ATG12 expression 2 d post-transfection with control or
ATG12 siRNA. Cell viability of control or ATG12 siRNA-transfected U2OS cells, treated with MG132 (C) HBSS (D) or Act D (E) was determined by SYTOX
Green staining using an Incucyte Imager; representative time-points shown (24 h MG132, 30 h HBSS, 24 h Act D). Graphs represent the mean C/¡ SEM
of 4 experiments. (F) U2OS, transfected with control or ATG12 siRNA, or stably expressing vector or BCL2L1 were starved in HBSS. After 48 h of starvation,
cells were washed, cultivated for 7 d in DMEM and colonies were stained with methylene blue. (G) U2OS cells were treated with HBSS (24 h), MG132
(16 h) or Act D (16 h) and examined for ATG12 expression. In all immunoblots, ACT was used as a loading control.
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Figure 5. Free ATG12 promotes cell death independent of autophagy (A) U2OS cells stably expressing vector, Strawberry or Strawberry-ATG4BC74A were
treated for 4 h with chloroquine and cell lysates were blotted for RFP and LC3B. U2OS cells stably expressing vector, Strawberry or Strawberry-ATG4BC74A
were transfected with control or ATG12 siRNA. (B) Following MG132 treatment (24 h) or (C) HBSS starvation (48 h), cell viability was determined by SYTOX
Green exclusion in an Incuyte Imager. Graphs show the mean C/¡ SEM of 3 (B) or 5 (C) experiments at representative time-points (24h MG132, 48 h
HBSS). Western blots show cell lysates of U2OS cells stably expressing vector, Strawberry or Strawberry-ATG4BC74A, transfected with control or ATG12
siRNA, treated for 8 h with MG132 (B) or HBSS (C) and probed for RFP, LC3B, and ATG12. In all immunoblots, ACT or TOMM20 were used as a loading
control.
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ATG12 is highly unstable. Free ATG12 was found to be directly
ubiquitinated and targeted for proteasomal degradation in an
autophagy-independent manner. Importantly, turnover of
ATG12 regulates its cytotoxic function such that ATG12 con-
tributes to proteasome inhibitor-mediated toxicity.
ATG12 is a member of the UBL protein family that com-
prises of approximately 20 diverse members.19 Although sharing
homology with ubiquitin, UBLs are typically neither ubiquiti-
nated nor targeted for proteasomal degradation. In contrast, we
find that the free form of ATG12 is directly ubiquitinated, most
likely on lysine residues, and rapidly degraded via the protea-
some. Mutation of individual lysine residues failed to effect
ATG12 ubiquitination arguing that ATG12 can be ubiquitinated
on multiple lysine residues. Supporting our findings, a recent
proteome-wide, mass-spectrometry based analysis of ubiquiti-
nated proteins has revealed several potential ubiquitin acceptor
lysines in ATG12.20 Besides ATG12, another UBL called ubiq-
uitin D (UBD) has also been found to be directly ubiquitinated
and targeted for proteasomal degradation.21,22 Direct ubiquitina-
tion of UBD appears essential for its degradation. In the case of
ATG12, direct ubiquitination promotes but is not required for
its degradation since nonubiquitinated ATG12 is still targeted
for proteasomal degradation (Fig. 3E). Moreover, while UBD
can target substrates for proteasomal degradation, this is not
apparent with ATG12 given the highly stable nature of the
ATG12–ATG5 conjugate that we and others have observed.14
Why there is a profound difference in stability between free
ATG12 and ATG12–ATG5 remains unclear. The possibility
that ATG5 masks a destabilizing region in ATG12 seems
unlikely given that disruption of the ATG12 and ATG5 binding
interface does not appear to destabilize the ATG12–ATG5 con-
jugate.16,23 Importantly, ATG12 proteasomal degradation nei-
ther requires autophagy nor an exposed C-terminal glycine (that
conjugates to ATG5 or ATG3) since ATG12 instability persisted
in various autophagy-deficient settings or following mutation of
the ATG12 C-terminal glycine to an alanine (a modification that
inhibits ATG12–ATG5 conjugation).15
Free ATG12 has recently been shown to promote mitochon-
drial-dependent apoptosis.13 Along similar lines, we find that
free ATG12 contributes to proteasome inhibitor and HBSS star-
vation-mediated apoptosis. Interestingly, we find that disruption
of the putative ATG12 BH3-domain effectively stabilizes it. The
presence or upregulation of ATG12 may be sufficient to sensitize
to cell death by antagonizing antiapoptotic BCL2 function. In
contrast, ATG12 played no role in Act D-induced apoptosis.
This differential contribution of ATG12 may be due to the rapid
depletion of free ATG12 following transcriptional inhibition by
Act D treatment relative to the other treatments. Importantly,
the cytotoxic effect of ATG12 appears to be independent of any
effect on autophagy.
In summary, our findings develop an emerging paradigm that
UBLs themselves can be directly modified by ubiquitin and tar-
geted for proteasomal degradation. Moreover, these results pro-
vide a new ATG12-mediated link between autophagy and
proteasome activity. Regulation of ATG12 degradation has the
potential to impact on both its expanding repertoire of
autophagy-independent functions as well as the clinical efficacy
of proteasome inhibitors utilized in cancer treatments.
Materials and Methods
Cells
All cell lines were maintained in DMEM high glucose
medium supplemented with 10% fetal calf serum, 2 mM gluta-
mine, 1 mM sodium pyruvate, 50 mM mercaptoethanol, and
penicillin/streptomycin. Atg7-deficient MEFs have been previ-
ously described.24 Atg12 knockout MEFs were derived from
atg12¡/- animals that will be described elsewhere (J.D., manu-
script in preparation). Drs. Masaaki Komatsu (Tokyo Metropoli-
tan Institute of Medical Science) and Mathew Albert (Pasteur
Institute) kindly provided Atg3- and Atg5-deficient MEFs,
respectively.
Retroviral transduction
Phoenix Ecotropic cells (0.5 £ 106 in a 10 cm dish) were
transfected with LZRS zeo, LZRS FLAG-BCL2L1, pLenti6puro
(pL6) Strawberry-ATG4BC74A or empty vector controls using
Lipofectamine 2000 (Invitrogen, 11668-019) according to the
manufacturer’s instructions. Two days later virus-containing
supernatant was harvested, filtered, and used to infect U2OS cells
in the presence of 1 mg/ml polybrene. Two days postinfection,
stably expressing cells were selected by growth in 200 ug/ml zeo-
cin (Invitrogen, R250-01) or 1 ug/ml puromycin (Sigma,
P8833), respectively.
Western blotting
Cell lysates were prepared using NP-40 lysis buffer (1% NP-
40 [Sigma, I8896], 1 mM EDTA, 150 mM NaCl, 50 mM Tris
pH 7.4, 1 mM phenylmethylsulfonyl fluoride [Sigma, 93482],
Complete Protease Inhibitors [Roche, 11697498001]). Protein
content was determined by Bio-Rad assay (Bio-Rad, 500-0006),
proteins were separated by SDS-PAGE and blotted onto nitrocel-
lulose. Membranes were probed with anti-ACT (actin) (MP Bio-
medicals, 08691001, 1/10000), anti-ATG12 (Cell Signaling
Technology, 4180, 1/1000), anti-UB/ubiquitin (Santa Cruz Bio-
technology, sc-8017, 1/1000), anti-TOMM20 (Santa Cruz Bio-
technology, sc-11415, 1/1000), anti-RFP (Rockland, 600-901-
379, 1/1000), anti-LC3B (Cell Signaling Technology, 2775, 1/
1000) antibodies followed by incubation with the appropriate
HRP conjugated secondary antibody (GE Healthcare, NA934V,
NXA931) and detection of immunoreactive proteins by ECL.
Cell-based ubiquitination assay
293T cells (1 £ 106) were transfected with 2.5 mg His-ubiq-
uitin25 and 2.5 mg pcDNA3 (Invitrogen, V790-20), pcDNA3
ATG12 or pcDNA3 ATG12[K-] using GeneJuice (Novagen,
70967) according to the manufacturer’s protocol. Forty-eight h
after transfection, cells were harvested in phosphate-buffered
saline (PBS; Thermo Scientific, BR0014G) and pellets were
resuspended in UBA buffer (6 M guanidinium HCl, 300 mM
NaCl, 50 mM NaH2PO4 pH 8.0, 100 mg/ml N-ethylmaleimide
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[Sigma, E3876]). Cell lysates were incubated overnight with His-
tag Dynabeads (Novex Life Technologies, 1003D) rotating at
4C. The next day samples were subjected to consecutive washes
in UBA, UBB (1:1 mix of UBA and UBC), UBC buffer
(300 mM NaCl, 50 mM Na2PO4 pH 8.0) and PBS. For SDS-
Page LDS sample buffer (Novex Life Technologies, NP0007)
was added containing 50 mM imidazole.
Plasmids and site-directed mutagenesis
ATG12 was cloned from pMT2 myc-ATG12 via BamHI and
EcoRI into pcDNA3 by standard cloning techniques. Site-
directed mutagenesis was performed using Phusion site-directed
mutagenesis kit (Thermo Scientific, F-541) according to the
manufacturer’s instructions.
siRNA transfection
U2OS (1.5 £ 105) cells were transfected with 100 nM non-
targeting control (Thermo Scientific, D-001210-02-05) siGE-
NOME human Atg12 SMARTpool siRNA (Thermo Scientific,
M-010212-02-0005), a mixture of 3 different Stealth RNAi oli-
gos against Atg5 (Invitrogen, HSS114103, HSS114104,
HSS190366) or the individual RNAi duplexes using Lipofect-
amine 2000 (Invitrogen, 11668027) according to the man-
ufacturer’s protocol. Twenty-four h post-transfection, cells were
analyzed by immunoblotting or subjected to cell death or auto-
phagic flux assays.
Treatments and cell death assays
For protein stability assays cells were treated with 1mg/ml
cycloheximide (Sigma, C7698-1G), 10 mM MG132 (Calbio-
chem, 474790) or 10 mM lactaystin (Enzo, BML-PI104-1000)
for 8 h unless otherwise indicated. Before starvation with HBSS
(Gibco, 14025-050), cells were washed for 4 times with PBS.
Actinomycin D (Calbiochem, 114666) was used at a concentra-
tion of 1 mM. Cell viability was determined using an Incucyte
FLR imaging system (Essen Bioscience, Ann Arbor, MI). Cells
were plated in medium containing 30 nM SYTOX Green (Invi-
trogen, S7020). Cells were treated as described, imaged every
30 min over a period of 3 d, and analyzed using Incucyte image
analysis software (Essen Bioscience). For quantification, the
SytoxGreen fluorescence was normalized to the confluency factor
of the respective well and the percentage of SYTOX Green-posi-
tive cells was calculated using the maximum SYTOX Green fluo-
rescence at 100% cell death. Alternatively, cell viability was
analyzed by flow cytometry using FACSCalibur (BD Biosciences,
San Jose, CA). For this purpose, cells were harvested following
24 h of treatment as indicated and stained with Alexa Fluor
647-ANXA5/annexin V (BioLegend, 640911) and 1 mg/ml pro-
pidium iodide according to the manufacturer’s protocols. Analy-
sis was performed using Cellquest Pro software (BD Biosciences).
Autophagic flux assays
To determine autophagic flux U2OS cells were treated for 8 h
with 20 mM leupeptin (Tocris, 1167) and for 4 h with 20 mM
NH4Cl or 100 nM bafilomycin A1 (LC Laboratories, B-1080).
Chloroquine (Sigma, C6628) was used at a concentration of 50
uM for a duration of 4 h.
Real-time PCR
RNA was isolated from E1A wt or Atg7 knockout MEFs using
QIAGEN RNeasy Mini Kit (Qiagen, 74104). 2 mg RNA per
sample were used for cDNA synthesis and PCR with DyNAmo
SYBR Green 2-step qRT-PCR kit (Thermo Scientific, F430-L).
PCR fragments were amplified 3 min at 95C, followed by 40
cycles of 20 sec at 95C, 30 sec at 57C, 30 sec at 72C and final
5 min at 72C. The following primers were used: Acta1 (actin, a
1, skeletal muscle) forward (CTAAGGCCAACCGTGAAAAG),
Acta1 reverse (ACCAGAGGCATACAGGGACA), Atg12 for-
ward (AACAAAGAAATGGGCTGTGG), Atg12 reverse
(TTGCAGTAATGCAGGACCAG).
Statistical analysis
For comparison of multiple groups, the 2-way Analysis of
Variance (ANOVA) followed by the Bonferroni post-test was
used. Analyses were performed using Prism 5.0 software
(GraphPad).
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